OncoSec Medical (ONCS) Initiated with a Buy at H.C. Wainwright

By Ryan Adsit

OncoSec Medical (NASDAQ: ONCS) received a Buy rating and a $4 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $1.51.

Selvaraju observed:

“Our price target is derived from a market value of $222M for OncoSec, which includes a discounted cash flow-based asset value for ImmunoPulse IL-12, with 15% discount rate, 0% terminal growth rate and 30% probability of success.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.0% and a 27.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OncoSec Medical with a $4.50 average price target, representing a 198.0% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $5 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $2.95 and a one-year low of $1.04. Currently, OncoSec Medical has an average volume of 928.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.